Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

@article{Arend2014InhibitionOW,
  title={Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.},
  author={Rebecca C. Arend and Angelina I. Londo{\~n}o-Joshi and Rajeev S Samant and Yonghe Li and Michael G. Conner and Bertha A. Hidalgo and Ronald D. Alvarez and Charles N. Landen and John Michael Straughn and Donald J Buchsbaum},
  journal={Gynecologic oncology},
  year={2014},
  volume={134 1},
  pages={112-20}
}
Objective. The Wnt/β-catenin pathway is known to regulate cellular proliferation and plays a role in chemoresistance. Niclosamide, an FDA approved salicyclamide derivative used for the treatment of tapeworm infections, targets the Wnt/β-catenin pathway. Therefore, the objective of this study was to investigate niclosamide as a potential therapeutic agent for ovarian cancer. Methods. Tumor cells isolated from 34 patients' ascites with primary ovarian cancer were treated with niclosamide (0.1 to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology • 2018

Similar Papers

Loading similar papers…